The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Nelarabine is in a class of medications called antimetabolites
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
Subscribe To Our Newsletter & Stay Updated
